a Purpose of review Aspirin-induced urticaria/angioedema is a major aspirinrelated hypersensitivity often associated with aspirinintolerant asthma. Genetic studies on aspirin-intolerant asthma have shown chronic overproduction of cysteinyl leukotrienes. The genetic analysis of aspirin-induced urticaria/angioedema is limited, however. Recent findings A recent study on HLA genotypes has suggested that the HLA alleles DRB1 Ã 1302 and DQB1 Ã 0609 may be genetic markers for aspirin-induced urticaria/angioedema. A polymorphism study that examined nine single-nucleotide polymorphisms of five leukotriene-related genes [ALOX5 (encoding 5-lipoxygenase), ALOX5AP (5-lipoxygenaseactivating protein), PTGS2 (cyclooxygenase 2), LTC4S (leukotriene C4 synthase), and CYSLTR1 (cysteinyl leukotriene receptor 1)] found that promoter polymorphisms of ALOX5 (À1708A>G) and CYSLTR1 (À634C>T) were significantly different between aspirin-intolerant asthma and aspirin-induced urticaria/ angioedema, suggesting different contributions to the lipoxygenase pathway. A second polymorphism study, conducted on histamine-related genes, did not find any significant associations with aspirin-induced urticaria/ angioedema for the genes HNMT (encoding histamine N-methyltransferase), HRH1 or HRH2 (encoding histamine receptor types 1 and 2 respectively), or the gene encoding high-affinity IgE receptor Ib (FceRIb); however, the FceRIa gene promoter polymorphism was significantly associated with aspirin-induced urticaria/angioedema. This finding has been supported by in vitro functional studies. Summary The HLA alleles DRB1 Ã 1302 and DQB1 Ã 0609, and the ALOX5 and FceRIa promoter polymorphisms, may contribute to the pathogenesis of aspirin-induced urticaria/ angioedema. Further investigation to identify candidate genetic markers would help to elucidate the pathogenic mechanism of this condition. 
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Introduction
Aspirin ingestion can induce several allergic reactions, such as aspirin-intolerant asthma (AIA), aspirin-induced urticaria/angioedema (AIU), anaphylaxis and, rarely, hypersensitivity pneumonitis [1, 2] . Among these, AIU is the most prevalent. Although the pathogenic mechanism of AIA is not completely understood, chronic overproduction of cysteinyl leukotrienes derived from cyclooxygenase inhibition is a consistent finding [3] [4] [5] [6] 7 ] . Recent studies have shown an increased number of cells expressing cysteinyl leukotriene receptor 1 (CYSLTR1) in the nasal mucosa, especially in AIA patients [8] , and have identified a promoter polymorphism of the CYSLTR1 gene related to increased expression [9] . In contrast with AIA, knowledge about the pathogenic mechanism of AIU is limited; however, recent reports [10] [11] [12] have suggested that overproduction of cysteinyl leukotrienes may be involved. In this review, we summarize recent findings on the molecular genetic mechanisms of AIU.
Clinical phenotype of aspirin-induced urticaria/angioedema
Aspirin ingestion can induce acute and chronic urticaria with angioedema, with chronic urticaria defined as patients suffering from daily urticaria symptoms for more than 6 weeks [1, 2, 10] . AIU can be confirmed by an oral aspirin challenge test [11, 12] . Based on oral aspirin challenge test results, chronic urticaria patients were classified into two groups: aspirin-intolerant chronic urticaria (AICU), and chronic urticaria with a negative response to aspirin (chronic idiopathic urticaria, CIU). In our recent study [13] , AICU patients were younger and had a higher atopy rate, higher total serum IgE, and a greater association with a history of asthma. No significant differences were noted in the prevalence of thyroid auto-antibodies, anti-nuclear antibody, or other clinical parameters between AICU and CIU patients.
Genetic approach to aspirin-induced urticaria/angioedema
Current studies to investigate the genetic mechanism of aspirin-induced urticaria/angioedema have been performed using two approaches. The first is to identify HLA gene markers for aspirin-induced urticaria/angioedema, and the second is to identify genetic polymorphisms that increase or decrease the susceptibility of this phenotype.
HLA gene markers for patients with aspirin-induced urticaria/angioedema
We have demonstrated an association between HLA genotype and AIU by using a high-resolution analysis technique, confirming a strong positive association between the HLA DRB1 Ã 1302 and HLA DQB1 Ã 0609 alleles in AIU [14 ] ; allelic frequencies of HLA DRB1 Ã 1302 and HLA DQB1 Ã 0609 were significantly higher in AIU patients than in AIA patients or in normal control subjects (Table 1) . When clinical parameters were analyzed according to the presence of these two alleles, the patients carrying HLA DRB1 Ã 1302 or HLA DQB1 Ã 0609 (28.2 AE 7.0 and 29.0 AE 6.9 years respectively) were significantly younger (by 10 years) than those without either allele (38.0 AE 13.6 and 36.4 AE 13.4 years respectively), indicating that patients with these alleles develop AIU at an earlier age. No significant differences were found in the other clinical parameters, including atopy and total serum IgE, between the two groups. It has been reported that AIU has been associated with various auto-antibodies [13, 15] . When we analyzed any associations between HLA DRB1 Ã 1302 and DQB1 Ã 0609 on the one hand, and the prevalence of serum anti-nuclear antibody, thyroid auto-antibodies and IgG to Helicobacter pylori on the other, no associations were found between them. These findings suggested that the HLA alleles DRB1 Ã 1302-DQB1 Ã
0609-DPB1
Ã 0201 may be a strong genetic marker for determining AIU phenotype [14 ] . Further studies will be needed to explore the genetic interactions between these HLA alleles and immunologic markers and gene polymorphisms.
Leukotriene-related gene polymorphisms in aspirin-induced urticaria/angioedema
Although there is no clear evidence for the involvement of cysteinyl leukotrienes in AIU, it has been proposed that they may participate in the pathogenesis of AIU, as in AIA [10] [11] [12] . Immunopharmacological studies have demonstrated that mast cells and basophils are activated to a greater extent in patients with AIU [16] . Mastalerz et al. [17] demonstrated the overproduction of cysteinyl leukotrienes in association with a polymorphism of the leukotriene C4 synthase gene (LTC4S), À444 A>C, in patients with chronic urticaria with aspirin sensitivity; the frequency of subjects carrying the C allele of LTC4S À444A>C was significantly higher among chronic urticaria patients with positive aspirin challenge than among patients who did not react to aspirin. Moreover, AIU was shown to be aggregated in families inheriting the LTC4S À444C allele [18 ] ; the frequency of the À444C allele
Genetics of aspirin-induced urticaria/angioedema Kim et al. 267 Table 1 Allele frequencies of HLA DRB1 and DQB1 in study subjects Ten frequent alleles in the aspirin-induced urticaria group are listed. AIA, aspirin-intolerant asthma; AIU, aspirin-induced urticaria/angioedema; NC, normal control; OR, odds ratio.
was significantly higher in patients who were sensitive to aspirin than in those who were not sensitive. No association was found, however, between the LTC4S À444A>C polymorphism with the phenotype of non-steroidal antiinflammatory drug (NSAID)-induced isolated periorbital angioedema in a Spanish population [19] or a Korean population [20 ] .
We also investigated the genetic polymorphisms of candidate genes encoding enzymes involved in leukotriene synthesis in a Korean population [20 ] . We examined nine single-nucleotide polymorphisms (SNPs) of four leukotriene-related genes: 5-lipoxygenase (ALOX5; À1708G>A, 270G>A and 1728G>A), 5-lipoxygenaseactivating protein (ALOX5AP; 218A>G), cyclooxygenase 2 (PTGS2: À162C>G, 10T>G and 228G>A), LTC4S (À444A>C), and CYSLTR1 (À634C>T). We found that the polymorphisms of ALOX5 (À1708G>A) and CYSLTR1 (À634C>T) showed significant differences in genotype frequency between AIU and AIA patients; the frequency of the ALOX5 À1708A allele was significantly higher in the AIU group than in the normal control group, whereas the frequency of the CYSLTR1 À634T allele was significantly lower in the AIU group than in the AIA group (Table 2) . These results suggest that ALOX5 and CYSLTR1 make different contributions to two major aspirin-related conditions, AIU and AIA, in the Korean population.
Histamine-related genes in chronic urticaria with aspirin sensitivity
Considering the pathogenic mechanism of AIU, we can speculate that polymorphisms of candidate genes involved in the release and metabolism of histamine and of histamine receptor genes may be associated with the AIU phenotype. We analyzed 11 known SNPs of the genes encoding high-affinity IgE receptor I (FceRIb), histamine N-methyltransferase (HNMT), histamine receptor type 1 268 Drug allergy (HRH1) and histamine receptor type 2 (HRH2) and their haplotypes in AIU patients, and compared the frequencies with those in patients exhibiting other drug allergies and in normal controls. No significant differences were observed in allele or genotype frequencies, and haplotype frequencies of all the SNPs of the FceRIb gene, HNMT, HRH1 and HRH2 were noted among the three groups, suggesting that the polymorphisms of the FceRIb gene and the three histamine-related genes might not contribute to the development of the AIU phenotype in the Korean population (Table 3 ) [21 ] .
Furthermore, we analyzed genetic polymorphisms of the FceRIa gene and found a significant association of two promoter polymorphisms (À344C>T and À95 T>C) with AICU (Table 4 ) [22] . In particular, the genotype
Genetics of aspirin-induced urticaria/angioedema Kim et al. 269 FceR1, high-affinity IgE receptor; HNMT, histamine N-methyltransferase gene; HRH1, histamine receptor type 1 gene; HRH2, histamine receptor type 2 gene; E, glutamate; G, glycine; T, threonine, I, isoleucine; AIU, aspirin-induced urticaria/angioedema; DA, other drug allergy; NC, normal controls; q, minor allele frequency; NS, not significant. Each P value was calculated with co-dominant, dominant, and recessive models. Logistic regression analysis was applied to control for age, sex, and atopy as co-variables. and allele containing À344T occurred with a significantly higher frequency in AICU patients than in control groups (aspirin-tolerant chronic urticaria/angioedema and normal controls), whereas no significant differences were noted in the genotype and allele frequencies of the À95T>C polymorphism between the AICU and normal control groups. In addition, the genetic variants of FceRIa À344C>T were shown to increase promoter activity in both the human A549 and rat RBL-2H3 cell lines. These findings suggest that the FceR1a À335C>T polymorphism may contribute to the development of AICU by increasing promoter activity. Further investigation is needed to elucidate whether this genetic variant can increase histamine release and/or augment mast cell signaling, which could lead to the release of proinflammatory mediators. Table 5 summarizes the genes representing the phenotype of AIU.
Conclusion
Further information on the genetic polymorphisms of candidate genes with supporting functional studies will make it possible to elucidate the molecular mechanism of AIU and to identify the candidate genetic markers for differentiating AIU from other aspirin-related allergic conditions, possibly leading to the development of new diagnostic markers and additional therapeutic targets. 
